CSF2 and melanoma: Intralesional therapy with talimogene laherparepvec (T-VEC), an oncolytic herpes simplex virus (HSV) type 1 modified to produce granulocyte-macrophage colony-stimulating factor (GM-CSF), aims to specifically target melanoma cells while sparing healthy tissue [11].